A detailed history of Southland Equity Partners LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Southland Equity Partners LLC holds 5,578 shares of NVO stock, worth $572,470. This represents 0.16% of its overall portfolio holdings.

Number of Shares
5,578
Previous 5,541 0.67%
Holding current value
$572,470
Previous $791 Million 16.04%
% of portfolio
0.16%
Previous 0.23%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$119.07 - $145.42 $4,405 - $5,380
37 Added 0.67%
5,578 $664 Million
Q2 2024

Jul 12, 2024

BUY
$122.71 - $146.91 $122 - $146
1 Added 0.02%
5,541 $791 Million
Q1 2024

Apr 12, 2024

BUY
$102.11 - $135.92 $11,538 - $15,358
113 Added 2.08%
5,540 $711 Million
Q4 2023

Jan 09, 2024

BUY
$87.78 - $105.45 $12,903 - $15,501
147 Added 2.78%
5,427 $561 Million
Q3 2023

Jan 02, 2024

BUY
$90.94 - $199.54 $245,538 - $538,758
2,700 Added 104.65%
5,280 $480 Million
Q2 2023

Jan 02, 2024

BUY
$155.98 - $172.65 $2,963 - $3,280
19 Added 0.74%
2,580 $418 Million
Q1 2023

Jan 02, 2024

SELL
$132.34 - $159.14 $661 - $795
-5 Reduced 0.19%
2,561 $408 Million
Q4 2022

Jan 02, 2024

BUY
$102.55 - $135.33 $5,947 - $7,849
58 Added 2.31%
2,566 $347 Million
Q3 2022

Jan 02, 2024

SELL
$95.28 - $116.93 $381 - $467
-4 Reduced 0.16%
2,508 $250 Million
Q2 2022

Jan 02, 2024

BUY
$103.24 - $121.81 $9,704 - $11,450
94 Added 3.89%
2,512 $280 Million
Q1 2022

Jan 02, 2024

SELL
$93.1 - $112.54 $2,513 - $3,038
-27 Reduced 1.1%
2,418 $269 Million
Q4 2021

Jan 02, 2024

BUY
$95.88 - $117.08 $1,629 - $1,990
17 Added 0.7%
2,445 $274 Million
Q3 2021

Jan 02, 2024

BUY
$84.42 - $106.62 $3,207 - $4,051
38 Added 1.59%
2,428 $233 Million
Q2 2021

Jan 02, 2024

BUY
$67.66 - $84.76 $161,707 - $202,576
2,390 New
2,390 $200 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $232B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Southland Equity Partners LLC Portfolio

Follow Southland Equity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Southland Equity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Southland Equity Partners LLC with notifications on news.